Positive results from first liver disease cell therapy trial
In a Nature Medicine publication, researchers from the University of Edinburgh’s MRC Centre for Regenerative Medicine (CRM; Edinburgh, Scotland) have reported promising results from the first clinical trial assessing the safety of a liver cirrhosis cell therapy
In a Nature Medicine publication, researchers from the University of Edinburgh’s MRC Centre for Regenerative Medicine (CRM; Edinburgh, Scotland) have reported promising results from the first clinical trial assessing the safety of a liver cirrhosis cell therapy. The treatment involves the reprograming of autologous blood cells into macrophages, which are then re-administered to patients. No adverse treatment effects were observed in the preliminary investigation and planning for the next stage of the trial is now underway.
Stuart Forbes, Professor and Chair of Transplantation and Regenerative Medicine at the CRM, commented: “Liver cirrhosis is a major healthcare issue in the UK and is one of the top five killers. The results from this first safety trial are encouraging and we can now progress to testing how effective it is in a larger group of people. If this was found to be effective it would offer a new way to tackle this important condition.”
ارسال به دوستان